Binosto® (buffered soluble alendronate 70mg) is indicated for the treatment of osteoporosis.
Binosto® is an effervescent tablet containing the active substance alendronic acid (commonly called alendronate) that represents an efficacious treatment option for osteoporosis. Binosto® is taken once a week as an oral solution. The effervescent tablet must be dissolved in half a glass of water. Binosto® thus prevents the risk of the tablet getting lodged in the esophagus. Binosto® represents a novel therapeutic option, especially for patients who prefer not to swallow tablets or have difficulties swallowing pills. Binosto® has the potential to improve long-term patient compliance and adherence to the therapy, thereby decreasing the risk of disabling fractures.
Switzerland: Binosto is indicated for the treatment of osteoporosis in postmenopausal women and men.2
Europe / UK: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.3
United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.
Visit www.binosto.com for U.S. approved prescribing information.
Disclaimer: Please refer to the official prescribing information in your country regarding the indications, contraindications and warnings.
Binosto® is commercialized in the United States and in selected countries in Europe, Middle East and Asia.
EffRx seeks to further expand Binosto’s footprint to countries where the product is not yet marketed, particularly in North Africa and Latin America.
1. Binosto Summary of Product Characteristics. June 2021;
3. Binosto Summary of Product Characteristics. June 2021 and www.medicines.org.uk/emc/product/7113/smpc#gref
Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenal insufficiency (AI).
Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone-containing granules in capsules for opening. that allows accurate age-appropriate dosing, especially in infants and children. This therapeutic approach has the potential to help young patients under the age of eighteen suffering from pediatric AI and congenital adrenal hyperplasia (CAH).
EffRx obtained the Swiss Marketing Authorization for Alkindi® as a replacement therapy for adrenal insufficiency in infants, children, and adolescents (from birth to less than eighteen years) in 2021. Alkindi® is now also available to patients in Switzerland, where around 200 children suffer from pediatric AI.
Efmody® is a modified-release hydrocortisone therapy that addresses a critical need in the management of congenital adrenal hyperplasia (CAH), offering a new treatment opportunity for patients with this rare genetic condition.
EffRx has obtained from Swissmedic the Marketing Authorization for Efmody® and is currently seeking reimbursement from FOPH to enable the introduction to the market.
The approval and planned market launch of Efmody® in Switzerland is a testament to EffRx’s commitment to expanding access to essential therapies for rare conditions, and emphasizes its role in transforming patient care in the field of congenital adrenal hyperplasia.
Miglustat Dipharma is an inhibitor of glucosylceramide synthase, the enzyme responsible for the first step in the synthesis of most glycolipids. The inhibitory action on glucosylceramide synthase forms the rationale for substrate reduction therapy in Gaucher disease type 1. Miglustat Dipharma is also indicated to reduce the progression of clinically relevant neurological symptoms in patients affected by Niemann-Pick type C disease, which are considered secondary to the abnormal accumulation of glycosphingolipids in neuronal and glial cells.1
EffRx is acting as Dipharma’s exclusive distributor for Miglustat Dipharma in Switzerland.
In Switzerland, EffRx Pharmaceuticals plays a pivotal role in ensuring that this medication is accessible to patients in need. The collaboration with Dipharma underscores our commitment to enhancing patient care and improving outcomes for those diagnosed with Gaucher disease or Niemann-Pick type C disease.
Metopiron text Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenal insufficiency (AI).
Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone-containing granules in capsules for opening. that allows accurate age-appropriate dosing, especially in infants and children. This therapeutic approach has the potential to help young patients under the age of eighteen suffering from pediatric AI and congenital adrenal hyperplasia (CAH).
EffRx obtained the Swiss Marketing Authorization for Alkindi® as a replacement therapy for adrenal insufficiency in infants, children, and adolescents (from birth to less than eighteen years) in 2021. Alkindi® is now also available to patients in Switzerland, where around 200 children suffer from pediatric AI.
Metopiron text Alkindi® is the first preparation of hydrocortisone specifically designed for and studied in children suffering from pediatric adrenal insufficiency (AI).
Alkindi® is a patented, oral, immediate-release formulation of hydrocortisone-containing granules in capsules for opening. that allows accurate age-appropriate dosing, especially in infants and children. This therapeutic approach has the potential to help young patients under the age of eighteen suffering from pediatric AI and congenital adrenal hyperplasia (CAH).
EffRx obtained the Swiss Marketing Authorization for Alkindi® as a replacement therapy for adrenal insufficiency in infants, children, and adolescents (from birth to less than eighteen years) in 2021. Alkindi® is now also available to patients in Switzerland, where around 200 children suffer from pediatric AI.
Binosto® is an effervescent tablet containing the active substance alendronic acid (commonly called alendronate) that represents an efficacious treatment option for osteoporosis. Binosto® is taken once a week as an oral solution. The effervescent tablet must be dissolved in half a glass of water. Binosto® thus prevents the risk of the tablet getting lodged in the esophagus. Binosto® represents a novel therapeutic option, especially for patients who prefer not to swallow tablets or have difficulties swallowing pills. Binosto® has the potential to improve long-term patient compliance and adherence to the therapy, thereby decreasing the risk of disabling fractures.
